Dipeptidyl peptidase 4 inhibitors and angiotensin II receptor blockers attenuate chronic kidney disease progression in experimental diabetic and non-diabetic nephropathy in a blood pressure and glucose independent manner, but the exact molecular mechanisms remain unclear. MicroRNAs (miRNAs) are short, non-coding RNA species that are important post-transcriptional regulators of gene expression and play an important role in the pathogenesis of nephropathy. miRNAs are present in urine in a remarkably stable form, packaged in extracellular vesicles. Here, we investigated linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in 5/6 nephrectomized rats. In the present study, renal miRNA profiling was conducted using the Nanostring nCounter technology and mRNA profiling using RNA sequencing from the following groups of rats: sham operated plus placebo; 5/6 nephrectomy plus placebo; 5/6 nephrectomy plus telmisartan; and 5/6 nephrectomy plus linagliptin. TaqMan Array miRNA Cards were used to evaluate which of the deregulated miRNAs in the kidney are present in urinary exosomes. In kidneys from 5/6 nephrectomized rats, the expression of 13 miRNAs was significantly increased (>1.5-fold, \( P < 0.05 \)), whereas the expression of 7 miRNAs was significantly decreased (>1.5-fold, \( P < 0.05 \)). Most of the deregulated miRNA species are implicated in endothelial-to-mesenchymal transition and inflammatory processes. Both telmisartan and linagliptin suppressed the induction of pro-fibrotic miRNAs, such as miR-199a-3p, and restored levels of anti-fibrotic miR-29c. In conclusion, the linagliptin and telmisartan-induced restorative effects on miR-29c expression were reflected in urinary exosomes, suggesting that miRNA profiling of urinary exosomes might be used as a biomarker for CKD progression and monitoring of treatment effects.

Chronic kidney disease (CKD) is a major global health problem associated with significant morbidity and mortality\(^1\). Hypertension and diabetes mellitus are known to be the main contributors to the development and progression of CKD in developed countries\(^2\). Reducing blood pressure using angiotensin II receptor blockers or angiotensin-converting enzyme is the first-line therapy for delaying CKD progression\(^3\). Despite the control of the renin-angiotensin system glycemic control is essential for therapies combating diabetic nephropathy.

Dipeptidyl peptidase (DPP)-4 inhibitors are indicated for the treatment of diabetes, however beneficial effects independent of glucose and renal blood pressure have been shown in animal models of both diabetic\(^4\) and non-diabetic CKD\(^5\). It is well known that the antidiabetic effects of DPP-4 inhibitors are mediated via increases in levels of the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulintropic polypeptide (GIP)\(^6\). Moreover, recent experimental data demonstrated that linagliptin exerts anti-inflammatory\(^7\),

\(^1\)Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine & Clinical Pharmacology, Biberach, Germany.\(^2\)Boehringer Ingelheim Pharma GmbH & Co. KG, Cardiometabolic Diseases Research, Biberach, Germany.\(^3\)Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany.\(^4\)Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt. *email: denis.delic@boehringer-ingelheim.com; berthold.hocher@medma.uni-heidelberg.de
accumulation of extracellular matrix (ECM) leading to fibrosis and hypertrophy in various kidney cell types. In diabetic and non-diabetic CKD pathogenesis TGF-β signaling is known to induce the synthesis and accumulation of extracellular matrix (ECM) leading to fibrosis and hypertrophy in various kidney cell types. TGF-β-induced expression of ECM genes during the development of diabetic nephropathy is mediated by several miRNA species. The functional crosslink between TGF-β and responsive miRNA expression has been demonstrated in renal cells, such as proximal tubular epithelial cells, mesangial cells and podocytes. Increased glomerular miR-21 level are positively associated with the albumin-creatinine ratio (ACR) in patients with diabetic nephropathy and it was postulated that altered miRNA-21 level might serve as an indicator of podocyte damage. Another prominent pro-fibrotic miRNA is miR-199a which is involved in the regulation of TGF-β signaling. Increased renal expression of miR-199a was observed in the unilateral ureteral obstruction mouse model and inhibits the expression of caveolin 1 which is a critical process in the activation of fibroblasts by TGF-β. In contrast, expression of kidney damage protective miRNAs, such as members of the miR-200-, miR-30- and miR-29-families, is decreased in various kidney cell types. miR-29 family members are down-regulated in CKD such as diabetic nephropathy, focal glomerulosclerosis, membranous nephropathy and IgA nephropathy. In vitro studies revealed that inhibition of overexpression of and knockdown of miR-29 enhanced TGF-β induced expression of collagens type I and III by renal tubular cells. Streptozotocin-induced diabetic miR-29 transgenic mice showed improved renal function and better podocyte viability whereas knockdown of miR-29 promoted podocyte apoptosis, proteinuria and subsequent renal dysfunction. The DPP-4 inhibitor linagliptin restored the level of renal miR-29a, which was associated with the inhibition of TGF-β-induced endothelial to mesenchymal transition (EndMT) in the kidneys of diabetic mice. Extracellular vesicles, such as exosomes, are secreted in large quantities from all nephron segments into the urine and may provide valuable insights into renal pathophysiology. Urinary exosomal miRNA content is altered in patients with focal segmental glomerulosclerosis, in type I diabetic patients with incipient diabetic nephropathy, and in type II diabetic patients with diabetic nephropathy. Moreover, it was shown that altered urinary exosomal miR-29c level might potentially serve as a predictor of early fibrosis in lupus nephritis.

In the present study we investigated the effects of linagliptin and compared with those of telmisartan which is one of the most commonly used ARBs on dysregulated miRNAs in the kidney in the rat 5/6 nephrectomy model, one of the most well-established experimental non-diabetic CKD models. We aimed to identify those effects on urinary exosomal miRNA level which might serve as potential novel biomarkers for monitoring both disease progression and treatment effects.

Materials and Methods

Experimental design. The aim of this study was to identify the effects of telmisartan and linagliptin on miRNAs differentially expressed in kidneys from 5/6 Nx rats and to assess whether these effects can be accurately quantified in urinary exosomes. As a first, step large-scale miRNA and mRNA expression profiles from the same renal tissue samples were evaluated using the Nanostring and RNA sequencing platforms, respectively. Changes in miRNA expression level were identified by a moderated t-test, evaluating only those miRNAs with at least 1.5-fold expression changes at a P-value < 0.05. In addition, P-values were further corrected for multiple testing according to Benjamini-Hochberg. Functional annotations of these miRNAs were searched in several databases including miRWalk (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk), TargetScan (http://www.targetscan.org), miRBase (http://www.mirbase.org), and PubMed (http://www.ncbi.nlm.nih.gov/pubmed). Inverse correlated miRNA-target mRNA pairs were identified using Ingenuity Pathway Analysis (http://www.qiagenbioinformatics.com). Highly predicted target miRNAs with a Spearman’s correlation coefficient of at least r = 0.7 were further assessed. Quantitative real-time polymerase chain reaction (PCR) was then used to detect differentially expressed renal miRNAs in urinary exosomes.

Animals. Eight week old Wistar rats were purchased from Charles River Laboratories International, Inc. (Wilmington, MA). This study (animal studies and protocols) was approved by the Committee on the Ethics of Animal Experiments (Landesamt fuer Gesundheit und Soziales), Berlin, Germany and is in accordance with University Guidelines for Use of Laboratory Animals. The animals were assigned into 4 groups: sham operation (sham) + placebo; 5/6 nephrectomy (5/6 Nx) + placebo; 5/6 Nx + telmisartan; 5/6 Nx + linagliptin. TheNx operation was performed as follows: uninephrectomy at Week 1, followed at Week 3 by amputation of the poles of the remaining kidney. Sham operations were performed at the same time points. Linagliptin (83 mg/kg/day in chow) and telmisartan (5 mg/kg/day in drinking water) were administered from Day 4 after the second surgery for 13 weeks. Immediately after this treatment period animals were sacrificed and organs were harvested. Urine albumin-to-creatinine ratio (UACR), interstitial fibrosis, plasma DPP-4 activity and urinary DPP-4 activity/creatinine ratios of the experimental groups are summarized in Table S1. Further physiology and biochemistry parameters of animals were described in detail by Tsuprykov et al. and isolated total RNA was used for the following experiments.

Nanostring analysis. Total RNA from kidney tissue was extracted using RNeasy Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany). RNA purity and quantity were assessed by NanoDrop 2000 (ThermoScientific, Waltham, MA, USA). Total RNA (100 ng) was used to assess the miRNA expression using the nCounter Rat v1.5 miRNA CodeSet (based on miRBase v17, Nanostring Technologies, Seattle, WA, USA) which contains a library of 420 probes. The purified complexes were quantified on the nCounter Digital Analyzer and analyzed by nSolver software (v1.1; Nanostring Technologies, Seattle, WA). The exact data analysis procedure can be found at: http://www.NanoString.com/media/pdf/MAN_nCounter_Gene_Expression_Data_Analysis_Guidelines.pdf.
mRNA library preparation, sequencing and data analysis. RNA sequencing libraries were prepared using Illumina’s TruSeq RNA Sample Prep Kit - v2 (Illumina Inc.) according to the manufacturer’s instructions. The library concentrations were then quantified with the Quant-iT PicoGreen dsDNA Assay Kit (Quant-iT) using CLARIOstar (BMG LABTECH) and the library quality was determined by checking cDNA fragment size using a DNA1000 Kit on the Agilent Bioanalyzer 2100 (Agilent Tech Inc.). Libraries were then normalized to 2 nM and subjected to cluster generation on a cBot system followed by single-read sequencing of 52 bp on an Illumina HiSeq. 2000 instrument (Illumina Inc.). Quality check (QC) of the obtained reads was performed using FASTQC v0.10.1. Based on RPKMs/FPKMs as obtained in the subsequent analysis (1.6.2), principal component analysis (PCA) and hierarchical clustering analysis were further used to identify outliers. Outliers were removed from subsequent analysis. Reads were then mapped to the human reference genome hg19 (GRCh37 Ensembl v. 70, primary assembly) using STAR v2.3.0e. Mapped reads were QCed using RNA-SeQC v1.1.7. Gene expression intensities are represented as either uRPKM/uFPKM or mRPKM/mFPKM values and these were calculated based on Ensembl v70 gene annotations using cufflinks v2.2.1 for Linux_x86_64. RPKM/FPKM values account for the different lengths of genes as well as different number of reads measured for the respective sample. Only those reads that could unambiguously be assigned to the respective gene were considered in the analysis to determine uRPKM/uFPKM values. For mRPKM/mFPKM values multiple mapping reads were also considered. SAM to

Figure 1. Principal component analysis of miRNA expression profiling results. Displayed are the first three major components from the principal component analysis. (green = sham + placebo; red = 5/6 Nx + placebo; blue = 5/6 Nx + telmisartan; yellow = 5/6 Nx + linagliptin).

(a) (b)
miR-142-3p 1
miR-190 1
miR-32 1
miR-203 1

downregulated miRNAs
miR-150 1
miR-199a-3p 1
miR-21 1

**Table 1.** Effects of telmisartan and linagliptin on differentially expressed miRNAs in kidney from 5/6 Nx rats. Values (fold changes) are given as mean ± SEM; *P < 0.05 5/6 Nx + placebo versus Sham + placebo; **P < 0.05 5/6 Nx + telmisartan versus 5/6 Nx + placebo; ***P < 0.05 5/6 Nx + linagliptin versus 5/6 Nx + placebo.

BAM conversion was done using picard-tools-1.77. Differential expression analysis was conducted based on read counts per gene. Read counts per gene (Ensembl v70 gene annotations) were either obtained using htsq-cquant from HTSeq v0.5.3p9 and samtools v0.1.18 or based on cufflinks v2.2.1 results. Fold changes and their respective significance were computed based on the read counts obtained for each gene using R and Bioconductor packages edgeR, DESeq2 or voom in conjunction with limma.

**Integrated analysis of miRNA and mRNA expression.** Spearman correlation coefficients (r_s) between miRNA and miRNA expression values for each sample were calculated. Correlation coefficients ranged from −1 to 1 and r_s < −0.7 were considered for further evaluation.

**Urinary exosomal miRNA expression.** The animals were placed in metabolic cages to obtain 24-hour urine samples. Urine samples from three animals were pooled due to the limited amount of urine, resulting in 4 samples in total per experimental group. Urinary exosomal miRNAs were isolated using the exoRNeasy Serum/
Plasma Maxi Kit (QIAGEN, Hilden, Germany) and the expression of the miRNAs was screened using Taqman Fast Advanced MasterMix (Applied Biosystems) and the rodent Taqman miRNA Array, Card A V.2.0 (Applied Biosystems). The gene expression analysis was run on a SDS7900HT real-time PCR system (Applied Biosystems by ThermoFisher Scientific). TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) and Megaplex RT Primers, Rodent Pool A v2.1 (Applied Biosystems) were used to reverse transcribe miRNAs. The RT products were pre-amplified using Megaplex RT Pre-Amp Primers, Rodent Pool A v2.1 (Applied Biosystems). U6snRNA was used for normalization. PCR reactions were performed with the TaqMan gene expression master mix (Life Technologies) according to the manufacturer’s protocol on a SDS7900HT real-time PCR System. Raw Ct values were calculated using the SDS software v2.4. Threshold cycle (Ct) values > 35 were excluded from any calculations. Fold change of expression was calculated using the comparative Ct method \(2^{-\Delta\Delta Ct}}\).

Statistical analysis. Differential expression was calculated applying the linear models approach incorporated in the limma software package\(^{25,26}\) using Tibco Spotfire version 6.5.2 (TIBCO Software, Palo Alto, USA). miRNAs > 1.5-fold and mRNAs > 1.5-fold differentially expressed between the compared groups with a P-value adjusted for multiple testing < 0.05 were considered to be significantly differentially expressed. Adjustment of P-values for multiple testing was performed according to Benjamini and Hochberg\(^{27}\). Heatmaps, principal component analyses and volcano plots were generated via Tibco Spotfire (TIBCO Software). Hierarchical clustering was calculated using unweighted pair group method with arithmetic mean as the default clustering method and Euclidean distance measure.

Statistical analysis for the PCR data was performed using ANOVA and Tukey’s multiple comparisons test. For group-wise comparisons, expression was considered significantly changed if the respective fold change was > 1.5 and P-value < 0.05.

Results

Effects of telmisartan and linagliptin on differentially expressed miRNAs in kidneys from 5/6 Nx rats. Principal component analysis revealed that the miRNA expression profiles were relatively similar within each experimental group whereas the respective groups clustered separately (Fig. 1). Compared with sham-operated animals, in 5/6 Nx-placebo-treated rats, the renal expression of the 13 miRNAs miR-142-3p, miR-195, miR-21, miR-150, miR-199a-3p, miR-199a-5p, miR-214, miR-223, miR-290, miR-322, miR-497, miR-532-5p and miR-542-5p was significantly up-regulated (Fig. 2a), whereas the renal expression of the 7 miRNAs miR-144, miR-190, miR-203, miR-29b, miR-29c, miR-32 and miR-451 was significantly down-regulated (Fig. 2b). Telmisartan significantly ameliorated the expression of miR-150, miR-199a-5p, miR-199a-3p, miR-223 and miR-214, whereas linagliptin significantly ameliorated the expression of miR-150, miR-199a-5p and miR-322 compared to the 5/6 Nx placebo group (Fig. 2a). Significant restoring effects on the expression of miR-29b, miR-29c and miR-32 were observed for both telmisartan- and linagliptin-treated 5/6 Nx rats compared to placebo-treated

Figure 3. Renal mRNA expression. Heatmap of renal gene expression of sham-operated (green box), placebo-treated 5/6 Nx (red box), telmisartan-treated (blue box) and linagliptin-treated 5/6 Nx (yellow box). Hierarchical clustering of all significantly deregulated mRNAs is depicted according to their log2-transformed expression levels (red = high; dark grey = low).
| miRNA      | 5/6Nx + placebo vs. Sham + placebo | 5/6Nx + telmisartan vs. Sham + placebo | Target miRNA | Target prediction | 5/6Nx + telmisartan vs. Sham + placebo | 5/6Nx + linagliptin vs. Sham + placebo | Function (www.genecards.org)                                                                                                                                 |
|------------|------------------------------------|----------------------------------------|--------------|------------------|----------------------------------------|----------------------------------------|---------------------------------------------------------------------------------------------|
| miR-532-5p | 2.46                               | 1.41                                   | HISP9        | Moderate          | 0.584 −0.783                          | −0.539                                  | 1.258 −0.964 This protein plays a role in cell proliferation, stress response and maintenance of the mitochondria. |
|            |                                    |                                        | VPS37A       | Moderate          | 0.659 −0.733                          | −0.576                                  | 1.337 −0.624 Required for the sorting of ubiquitinated transmembrane proteins into internal vesicles of multivesicular bodies. |
|            |                                    |                                        | ALS2         | High              | 0.606 −0.867                          | −0.309                                  | 1.180 −0.733 The protein functions as a guanine nucleotide exchange factor for the small GTPase RAB5. |
|            |                                    |                                        | ANKRDI3C     | High              | 0.625 −0.900                          | −0.309                                  | 1.261 −0.806 Acts as a molecular chaperone for G protein-coupled receptors. |
|            |                                    |                                        | ARHGEF28     | Moderate          | 0.664 −0.767                          | −0.406                                  | 1.120 −0.552 Functions as a RHOA-specific guanine nucleotide exchange factor regulating signaling pathways downstream of integrins and growth factor receptors. |
|            |                                    |                                        | ARHGEF5      | High              | 0.651 −0.767                          | −0.358                                  | 1.032 −0.552 The encoded protein may form a complex with G proteins and stimulate Rh-dependent signals. This protein may be involved in the control of cytoskeletal organization. |
|            |                                    |                                        | CAPRIN1      | High              | 0.553 −0.800                          | −0.394                                  | 1.383 −0.830 May regulate the transport and translation of mRNAs of proteins involved in synaptic plasticity in neurons and cell proliferation and migration in multiple cell types. |
|            |                                    |                                        | EDNRB        | Moderate          | 0.480 −0.750                          | −0.188                                  | 0.556 −0.455 The protein encoded by this gene is a G protein-coupled receptor which activates a phosphatidylinositol-calcium second messenger system. |
|            |                                    |                                        | FAD56        | High              | 0.367 −0.700                          | 1.909                                   | 0.139 −0.685 Involved in oleate biosynthesis. |
|            |                                    |                                        | FZD4         | High              | 0.467 −0.717                          | 1.272                                   | −0.297 0.107 −0.576 Involved in the beta-catenin (CTNNB1) canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin (CTNNB1) and activation of Wnt target genes. |
|            |                                    |                                        | GOSR1        | High              | 0.586 −0.833                          | 1.080                                   | −0.333 0.959 −0.661 Involved in transport from the ER to the Golgi apparatus as well as in intra-Golgi transport. It belongs to a super-family of proteins called t-SNAREs or soluble NSF (N-ethylmaleimide-sensitive factor) attachment protein receptor. |
|            |                                    |                                        | HISP9        | Moderate          | 0.584 −0.817                          | 1.348                                   | −0.297 1.258 −0.806 This protein plays a role in cell proliferation, stress response and maintenance of the mitochondria. |
|            |                                    |                                        | JAKAMP       | Moderate          | 0.642 −0.800                          | 1.312                                   | −0.564 1.329 −0.564 Facilitates degradation of misfolded endoplasmic reticulum (ER) luminal proteins through the recruitment of components of the proteasome and endoplasmic reticulum-associated degradation (ERAD) system. |
|            |                                    |                                        | MAGI2        | Moderate          | 0.338 −0.833                          | 1.379                                   | −0.382 1.451 −0.673 Enhances the ability of FTY720 to suppress AKT1 activation. Plays a role in in vivo growth factor (NGF)-induced recruitment of RAPGEF2 to late endosomes and neurite outgrowth. |
|            |                                    |                                        | MCFD2        | High              | 0.616 −0.833                          | 1.308                                   | −0.661 1.335 −0.588 The MCFD2-LMAN1 complex forms a specific cargo receptor for the ER to Golgi transport of selected proteins. Plays a role in the secretion of coagulation factors. |
|            |                                    |                                        | NETO2        | Moderate          | 0.421 −0.767                          | 1.318                                   | −0.139 0.937 −0.600 This gene encodes a predicted transmembrane protein containing two extracellular CUB domains followed by a low-density lipoprotein class A (LDLα) domain. |
|            |                                    |                                        | NT5DC1       | Moderate          | 0.659 −0.700                          | 1.204                                   | −0.309 1.225 −0.879 Miscellaneous. |
|            |                                    |                                        | PDE4DIP      | Moderate          | 0.558 −0.700                          | 1.443                                   | −0.285 1.159 −0.515 The protein encoded by this gene serves to anchor phosphodiesterase 4D to the Golgi/centrosome region of the cell. |
|            |                                    |                                        | PPP1R2       | High              | 0.610 −0.767                          | 1.175                                   | −0.176 1.034 −0.576 The protein encoded by this gene binds to the catalytic subunit of protein phosphatase 1, strongly inhibiting its activity. |
|            |                                    |                                        | SCNN1G       | Moderate          | 0.555 −0.733                          | 1.466                                   | −0.200 1.384 −0.491 Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. |
|            |                                    |                                        | SDPR         | Moderate          | 0.466 −0.817                          | 1.357                                   | −0.345 1.288 −0.709 Plays an important role in caveolar biogenesis and morphology. Regulates caveolae morphology by inducing membrane curvature within caveolae. |
|            |                                    |                                        | SLC4A5       | High              | 0.595 −0.767                          | 1.698                                   | 0.261 1.349 −0.539 Miscellaneous. |
|            |                                    |                                        | TBC1D14      | High              | 0.567 −0.783                          | 1.271                                   | −0.152 1.259 −0.515 Negative regulator of starvation-induced autophagosome formation. |
|            |                                    |                                        | VEGFA        | High              | 0.465 −0.800                          | 1.528                                   | −0.224 1.443 −0.721 Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. |

Continued
miR-199a-3p

| miRNA | miR-199a-3p | 5/6 Nx + placebo vs. Sham + placebo | 5/6 Nx + telmisartan vs. Sham + placebo | Target mRNA | Target prediction | 5/6 Nx + placebo vs. Sham + placebo | 5/6 Nx + telmisartan vs. Sham + placebo | Target Function (www.genecards.org) |
|-------|-------------|-------------------------------------|----------------------------------------|------------|----------------|-------------------------------------|----------------------------------------|----------------------------------|
| ARL15 | Moderate    | 0.403 -0.708 1.344 -0.309 1.433 -0.079 | | | | | | | Miscellaneous. |
| ATP6V1A | Moderate   | 0.552 -0.783 1.345 -0.091 1.420 -0.358 | | | | | | | This gene encodes a component of vacuolar ATPase (V-ATPase), a multisubunit enzyme that mediates acidification of eukaryotic intracellular organelles. |
| CAPRIN1 | High       | 0.553 -0.783 1.287 -0.103 1.383 -0.394 | | | | | | | May regulate the transport and translation of mRNAs of proteins involved in synaptic plasticity in neurons and cell proliferation and migration in multiple cell types. |
| COBL1 | Moderate    | 0.494 -0.733 1.543 0.055 1.218 -0.212 | | | | | | | Miscellaneous. |
| DBT | Moderate    | 0.501 -0.783 1.474 0.212 1.498 -0.442 | | | | | | | The branched-chain alpha-keto-dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO2. |
| KCNJ13 | Moderate   | 0.439 -0.833 2.294 0.030 1.940 -0.430 | | | | | | | This gene encodes a member of the inwardly rectifying potassium channel family of proteins. |
| MAP3K5 | Moderate    | 0.556 -0.750 1.380 0.370 1.326 0.030 | | | | | | | Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. |
| MCFD2 | High       | 0.616 -0.767 1.308 -0.164 1.335 -0.127 | | | | | | | This protein forms a complex with LMAN1 (lectin mannose binding protein 1; also known as ERGIC-53) that facilitates the transport of coagulation factors V (FV) and VIII (FVIII) from the endoplasmic reticulum to the Golgi apparatus via an endoplasmic reticulum Golgi intermediate compartment (ERGIC). |
| NCOA4 | Moderate    | 0.427 -0.767 1.482 0.164 1.611 -0.200 | | | | | | | This gene encodes an androgen receptor coactivator. |
| PDE8A | Moderate    | 0.611 -0.783 1.302 -0.042 1.139 -0.055 | | | | | | | This PDE hydrolyzes the second messenger, cAMPS, which is a regulator and mediator of a number of cellular responses to extracellular signals. |
| PTGR2 | High       | 0.611 -0.783 1.545 0.103 1.541 -0.661 | | | | | | | This gene encodes an enzyme involved in the metabolism of prostaglandins. The encoded protein catalyzes the NADPH-dependent conversion of 15-keto-prostaglandin E2 to 15-keto-13,14-dihydro-prostaglandin E2. |
| PTPR1 | Moderate    | 0.435 -0.767 1.436 0.273 1.587 -0.248 | | | | | | | Tyrosine-protein phosphatase which dephosphorylates CTNNB1. Regulates CTNNB1 function both in cell adhesion and signaling. |
| RHOT1 | Moderate    | 0.622 -0.767 1.270 0.200 1.292 -0.527 | | | | | | | Mitochondrial GTPase involved in mitochondrial trafficking. |
| SDC2 | Moderate    | 0.608 -0.700 1.399 -0.297 1.403 -0.673 | | | | | | | The protein encoded by this gene is a transmembrane (type I) heparan sulfate proteoglycan and is a member of the syndecan proteoglycan family. |
| SEMA3E | Moderate    | 0.457 -0.700 1.282 0.103 1.305 0.079 | | | | | | | Plays an important role in signaling via the cell surface receptor PLXND1. Mediates reorganization of the actin cytoskeleton, leading to the retraction of cell projections. |
| SLC33A1 | Moderate | 0.615 -0.867 1.395 -0.030 1.248 -0.418 | | | | | | | Probable acetyl-CoA transporter necessary for O-acetylation of gangliosides. |
| ACSL1 | Moderate | 0.540 -0.733 1.634 0.139 1.472 -0.697 | | | | | | | Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. |
| ATP2A2 | High | 0.604 -0.883 1.343 -0.685 1.310 -0.685 | | | | | | | This gene encodes one of the SERCA (Ca2+)-ATPases, which are intracellular pumps located in the sarcoplasmic or endoplasmic reticulum of muscle cells. |
| KNCJ10 | Moderate | 0.289 -0.767 1.753 -0.491 1.150 -0.661 | | | | | | | This gene encodes a member of the inward rectifier-type potassium channel family, characterized by having a greater tendency to allow potassium to flow into, rather than out of, a cell. |
| ME1 | Moderate | 0.595 -0.867 2.030 -0.467 1.864 -0.479 | | | | | | | This gene encodes a cytosolic, NADP-dependent enzyme that generates NADPH for fatty acid biosynthesis. |
| PDE8A | High | 0.611 -0.700 1.302 -0.455 1.139 -0.564 | | | | | | | This PDE hydrolyzes the second messenger, cAMP, which is a regulator and mediator of a number of cellular responses to extracellular signals. |
| PICALM | High | 0.608 -0.800 1.159 -0.406 1.069 -0.697 | | | | | | | This gene encodes a clathrin assembly protein, which recruits clathrin and adaptin protein complex 2 (AP2) to cell membranes at sites of coated-pit formation and clathrin-vesicle assembly. |
| SLC33A1 | Moderate | 0.615 -0.717 1.395 -0.455 1.248 -0.733 | | | | | | | Probable acetyl-CoA transporter necessary for O-acetylation of gangliosides. |
| SYPL1 | High | 0.641 -0.817 1.175 -0.491 1.179 -0.782 | | | | | | | Miscellaneous. |

Continued
| miRNA | 5/6 Nx + placebo vs. Sham + placebo | 5/6 Nx + telmisartan vs. Sham + placebo | 5/6 Nx + linagliptin vs. Sham + placebo | Target mRNA | Target prediction | 5/6 Nx + telmisartan vs. Sham + placebo | 5/6 Nx + placebo vs. Sham + placebo | 5/6 Nx + linagliptin vs. Sham + placebo | Target mRNA | Function (www.genecards.org) |
|-------|----------------------------------|---------------------------------------|---------------------------------------|------------|-----------------|---------------------------------------|-------------------------------------|---------------------------------------|------------|---------------------------------|
| ADAM19| High                             | 3.196                                 | 0.750                                 | 0.442      | 0.297           | 0.519                                 | 0.200                                | Participates in the proteolytic processing of beta-type neuregulin isoforms which are involved in neurogenesis and synaptogenesis, suggesting a regulatory role in glial cell. |
| ADAMTS7| High                             | 2.117                                 | 0.883                                 | 0.590      | 0.491           | 0.553                                 | 0.406                                | Metalloprotease that may play a role in the degradation of COMP. Plays a role in the mitochondrial apoptotic process. |
| BAK1 | High                             | 1.831                                 | 0.767                                 | 0.674      | 0.164           | 0.786                                 | 0.394                                | The protein encoded by this gene is one of several proteins that interact with NEDD4, a member of a family of ubiquitin-proteins ligases. |
| BEAN1 | High                             | 3.688                                 | 0.867                                 | 0.271      | 0.382           | 0.274                                 | 0.309                                | Anti-proliferative protein; the function is mediated by association with deadenylase subunits of the CCR4-NOT complex. |
| BMP1 | High                             | 1.590                                 | 0.700                                 | 0.605      | 0.127           | 0.715                                 | 0.248                                | Cleaves the C-terminal propeptides of procollagen I, II and III. Induces cartilage and bone formation. |
| BTG2 | High                             | 2.068                                 | 0.733                                 | 0.403      | 0.430           | 0.538                                 | 0.418                                | |
| C1QTNF6| High                             | 2.791                                 | 0.950                                 | 0.481      | 0.394           | 0.571                                 | 0.479                                | |
| CCNF | Moderate                         | 3.446                                 | 0.867                                 | 0.350      | 0.285           | 0.688                                 | 0.430                                | Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of CPII during G2 phase, thereby acting as an inhibitor of centrosome reduplication. |
| CCSAP | High                             | 2.038                                 | 0.783                                 | 0.570      | 0.200           | 0.589                                 | 0.188                                | Plays a role in microtubule (MT) stabilization and this stabilization involves the maintenance of NUMA1 at the spindle poles. |
| CD276 | Experimentally Observed          | 3.305                                 | 0.867                                 | 0.388      | 0.115           | 0.595                                 | 0.333                                | The protein encoded by this gene belongs to the immunoglobulin superfamily, and thought to participate in the regulation of T-cell-mediated immune response. |
| COL1A1| High                             | 2.150                                 | 0.900                                 | 0.399      | 0.527           | 0.685                                 | 0.588                                | This gene encodes one of the two alpha chains of type XI collagen, a minor fibrillar collagen. |
| COL1A1| Experimentally Observed          | 4.282                                 | 0.700                                 | 0.389      | 0.091           | 0.501                                 | 0.188                                | This gene encodes the pro-alpha1 chains of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. |
| COL1A2| Experimentally Observed          | 2.212                                 | 0.800                                 | 0.449      | 0.588           | 0.546                                 | 0.067                                | This gene encodes the pro-alpha2 chain of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. |
| COL3A1| Experimentally Observed          | 3.562                                 | 0.783                                 | 0.298      | 0.624           | 0.436                                 | 0.224                                | This gene encodes the pro-alpha1 chains of type III collagen. |
| COL4A1| Experimentally Observed          | 1.902                                 | 0.850                                 | 0.675      | 0.067           | 0.874                                 | 0.200                                | This gene encodes a type IV collagen alpha protein. Type IV collagen proteins are integral components of basement membranes. |
| COL6A2| High                             | 2.635                                 | 0.733                                 | 0.558      | 0.091           | 0.684                                 | 0.067                                | Collagen VI is a major structural component of microfibrils. |
| DTX4 | High                             | 2.249                                 | 0.917                                 | 0.596      | 0.164           | 0.700                                 | 0.200                                | Regulator of Notch signaling, a signaling pathway involved in cell-cell communications that regulates a broad spectrum of cell-fate determinations. |
| DYNLT1| High                             | 1.771                                 | 0.883                                 | 0.695      | 0.091           | 0.833                                 | 0.382                                | Plays a role in neuronal morphogenesis; the function is independent of cytoplasmic dynein and seems to be coupled to regulation of the actin cytoskeleton by enhancing Rac1 activity. |
| FAM131B| High                             | 3.386                                 | 0.767                                 | 0.144      | 0.406           | 0.632                                 | 0.091                                | Miscellaneous. |
| FBN1 | Experimentally Observed          | 2.345                                 | 0.833                                 | 0.373      | 0.648           | 0.477                                 | 0.345                                | Fibronillin-1 is an extracellular matrix glycoprotein that serves as a structural component of calcium-binding microfibrils. |
| FCRL1 | Moderate                         | 5.053                                 | 0.717                                 | 0.374      | 0.503           | 0.469                                 | 0.127                                | This gene encodes a protein similar to receptors for the Fc fragment of gamma immunoglobulin (IgG). |
| HBEGF | High                             | 2.125                                 | 0.850                                 | 0.403      | 0.382           | 0.472                                 | 0.673                                | Growth factor that mediates its effects via EGFR, ERBB2 and ERBB4. |
| IL24 | High                             | 48.632                                | 0.900                                 | 0.050      | 0.418           | 0.321                                 | 0.418                                | This gene encodes a member of the IL10 family of cytokines. It was identified as a gene induced during early semana in melanoma cells. |
| ITGA11| High                             | 6.767                                 | 0.817                                 | 0.574      | 0.115           | 0.777                                 | 0.103                                | Integrin alpha-11/beta-1 is a receptor for collagen. |
| KLF4 | Experimentally Observed          | 1.757                                 | 0.817                                 | 0.490      | 0.636           | 0.521                                 | 0.552                                | Involved in the differentiation of epithelial cells and may also function in skeletal and kidney development. |
| MAP6 | High                             | 2.761                                 | 0.867                                 | 0.580      | 0.055           | 0.631                                 | 0.285                                | Involved in microtubule stabilization in many cell types, including neuronal cells. |
| MMP2 | High                             | 2.823                                 | 0.783                                 | 0.404      | 0.636           | 0.561                                 | 0.297                                | The protein encoded by this gene is a gelatinase A, type IV collagenase, that contains three fibronectin type II repeats in its catalytic site that allow binding of denatured type IV and V collagen and elastin. |

Continued
| miRNA | 5/6 Nx + placebo vs. Sham + placebo | 5/6 Nx + telmisartan vs. Sham + placebo | Target miRNA | Target prediction | 5/6 Nx + placebo vs. Sham + placebo | 5/6 Nx + telmisartan vs. Sham + placebo | Function ([www.genecards.org](http://www.genecards.org)) |
|-------|-----------------------------------|---------------------------------------|-------------|------------------|-----------------------------------|---------------------------------------|----------------------------------------|
| miR-29 | 0.63 1.15 1.09 | | MPEG1 | Moderate | 2.891 | 0.733 0.309 | 0.539 0.406 | 0.576 | Miscellaneous. |
|       |                                   | | PDGFRB | High | 1.887 | −0.700 0.542 | −0.164 0.633 | −0.103 | The protein encoded by this gene is a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor receptor family. |
|       |                                   | | PIK3R1 | Experimentally Observed | 2.131 | −0.817 0.366 | −0.176 0.579 | −0.394 | Necessary for the insulin-stimulated increase in glucose uptake and glycolysis and synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to PGRF, FGFR2, FGFR3 and PDGFRB. |
|       |                                   | | PLC5R3 | High | 1.696 | −0.800 0.730 | −0.042 0.741 | 0.030 | May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. |
|       |                                   | | PMP22 | High | 1.793 | −0.767 0.470 | −0.406 0.499 | −0.285 | Might be involved in growth regulation, and in myelination in the peripheral nervous system. |
|       |                                   | | RAB31 | Moderate | 1.882 | −0.717 0.488 | −0.358 0.637 | −0.309 | Required for the integrity and for normal function of the Golgi apparatus and the trans-Golgi network. Plays a role in insulin-stimulated translocation of GLUT4 to the cell membrane. |
|       |                                   | | RG56 | Moderate | 4.951 | −0.733 0.198 | −0.309 0.364 | −0.236 | Regulates G protein-coupled receptor signaling cascades. |
|       |                                   | | SPARC | Experimentally Observed | 2.285 | −0.900 0.568 | −0.139 0.725 | −0.188 | The encoded protein is required for the collagen bone to become calcified but is also involved in extracellular matrix synthesis and promotion of changes to cell shape. |
|       |                                   | | TGFβ2 | High | 2.894 | −0.800 0.347 | −0.212 0.497 | −0.127 | This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. |
|       |                                   | | TMEM229B | High | 2.470 | −0.900 0.459 | −0.564 0.599 | −0.636 | Miscellaneous. |
|       |                                   | | TNFAIP3 | High | 2.278 | −0.867 0.444 | −0.588 0.470 | −0.770 | The protein encoded by this gene is a zinc finger protein and ubiquitin-editing enzyme, and has been shown to inhibit NF-kappa B activation as well as TNF-mediated apoptosis. |
|       |                                   | | TNFRSF1A | High | 2.353 | −0.800 0.578 | −0.030 0.714 | −0.188 | Binding of membrane-bound tumor necrosis factor alpha to the membrane-bound receptor induces receptor trimerization and activation, which plays a role in cell survival, apoptosis, and inflammation. |
|       |                                   | | VASH1 | High | 2.119 | −0.950 0.385 | −0.442 0.461 | −0.758 | Inhibits migration, proliferation and network formation by endothelial cells as well as angiogenesis. |
| miR-203 | 0.62 0.75 0.72 | | AP1S2 | High | 2.730 | −0.850 0.346 | −0.176 0.490 | −0.867 | Subunit of clathrin-associated adaptor protein complex 1 that plays a role in protein sorting in the late-Golgi/trans-Golgi network (TGN) and/or endosomes. |
|       |                                   | | BCL11B | High | 3.109 | −0.783 0.441 | 0.018 0.446 | −0.758 | Essential in controlling the responsiveness of hematopoietic stem cells to chemotherapeutic signals by modulating the expression of the receptors CCR7 and CCR9, which direct the movement of progenitor cells from the bone marrow to the thymus. |
|       |                                   | | BIRC5 | High | 3.097 | −0.800 0.577 | −0.576 0.819 | −0.818 | This gene is a member of the inhibitor of apoptosis (IAP) gene family, which encode negative regulatory proteins that prevent apoptotic cell death. |
|       |                                   | | CCR1 | Moderate | 4.032 | −0.833 0.215 | 0.297 0.522 | −0.673 | Receptor for a C-C type chemokine. Binds to MIP-1 alpha, MIP-1 delta. RANTES, and MCP-3 and, less efficiently, to MIP-1 beta or MCP-1 and subsequently transduces a signal by increasing the intracellular calcium ions level. |
|       |                                   | | CKAP2 | High | 3.743 | −0.983 0.147 | −0.564 0.861 | −0.855 | This gene encodes a cytoskeleton-associated protein that stabilizes microtubules and plays a role in the regulation of cell division. |
|       |                                   | | CTSS | High | 2.408 | −0.783 0.464 | −0.212 0.664 | −0.818 | The protein encoded by this gene, a member of the peptidase C1 family, is a lysosomal cysteine protease that may participate in the degradation of antigenic proteins to peptides for presentation on MHC class II molecules. |
|       |                                   | | DYNLTI | Moderate | 1.771 | −0.767 0.695 | −0.685 0.833 | −0.879 | Plays a role in neuronal morphogenesis, the function is independent of cytoplasmic dynein and seems to be coupled to regulation of the actin cytoskeleton by enhancing Rac1 activity. |

Continued
Table 2. Differential regulated miRNAs in 5/6 Nx + placebo/+ telmisartan/+ linagliptin compared to Sham + placebo rats and their corresponding target mRNAs. *miR-29 represents miR-29a/b/c.

| miRNA     | 5/6Nx vs Sham + placebo | 5/6Nx vs telmisartan vs Sham + placebo | 5/6Nx vs linagliptin vs Sham + placebo | Target mRNA | Target prediction | 5/6Nx vs Sham + placebo | 5/6Nx vs telmisartan vs Sham + placebo | 5/6Nx vs linagliptin vs Sham + placebo | Function (www.genecards.org) |
|-----------|-------------------------|----------------------------------------|---------------------------------------|-------------|-------------------|------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| miR-203   | 0.62                    | 0.75                                   | 0.72                                  | EDTNR       | High              | 1.803                  | −0.800                               | 0.533                                 | −0.152                               | 0.590 −0.539                        |
|           |                         |                                        |                                       | EVL2B       | High              | 3.594                  | −0.800                               | 0.355                                 | −0.333                               | 0.607 −0.818                        |
|           |                         |                                        |                                       | FGL2        | High              | 2.302                  | −0.750                               | 0.373                                 | −0.030                               | 0.563 −0.685                        |
|           |                         |                                        |                                       | HBEGF       | High              | 2.125                  | −0.733                               | 0.403                                 | −0.697                               | 0.472 −0.745                        |
|           |                         |                                        |                                       | IL24        | High              | 48.632                 | −0.817                               | 0.050                                 | −0.455                               | 0.321 −0.806                        |
|           |                         |                                        |                                       | NFI3        | High              | 2.512                  | −0.817                               | 0.472                                 | −0.588                               | 0.673 −0.685                        |
|           |                         |                                        |                                       | NRG2        | High              | 3.680                  | −0.833                               | 0.499                                 | −0.430                               | 0.570 −0.394                        |
|           |                         |                                        |                                       | NUMBL       | High              | 3.142                  | −0.833                               | 0.326                                 | −0.055                               | 0.484 −0.612                        |
|           |                         |                                        |                                       | PCSK2       | High              | 2.655                  | −0.867                               | 0.331                                 | −0.370                               | 0.604 −0.406                        |
|           |                         |                                        |                                       | PHLD3       | High              | 2.373                  | −0.750                               | 0.639                                 | −0.152                               | 0.670 −0.527                        |
|           |                         |                                        |                                       | POU2AF1     | Moderate          | 2.930                  | −0.783                               | 0.465                                 | −0.176                               | 0.549 −0.515                        |
|           |                         |                                        |                                       | PRC1        | Moderate          | 3.440                  | −0.867                               | 0.332                                 | −0.552                               | 0.790 −0.842                        |
|           |                         |                                        |                                       | PRKCB       | High              | 2.753                  | −0.883                               | 0.416                                 | −0.358                               | 0.457 −0.636                        |
|           |                         |                                        |                                       | RAB31       | High              | 1.882                  | −0.717                               | 0.488                                 | −0.236                               | 0.637 −0.758                        |
|           |                         |                                        |                                       | RELT        | Moderate          | 3.500                  | −0.700                               | 0.313                                 | −0.067                               | 0.417 −0.830                        |
|           |                         |                                        |                                       | SCEL        | High              | 3.231                  | −0.833                               | 0.215                                 | −0.152                               | 0.293 −0.455                        |
|           |                         |                                        |                                       | TGFβ2       | High              | 2.894                  | −0.750                               | 0.347                                 | −0.127                               | 0.497 −0.576                        |
|           |                         |                                        |                                       | ZC3H11D     | High              | 2.928                  | −0.933                               | 0.284                                 | −0.467                               | 0.546 −0.818                        |

The table shows the differential regulated miRNAs and their corresponding target mRNAs. The functions of the miRNAs are listed based on the miR-29 family. The target mRNAs are involved in various cellular processes such as regulation and activation of cell cycle progression, and survival of hematopoietic progenitor cells. The functions of the miRNAs are based on the gene cards database.
Figure 4. Gene set enrichment analysis of miRNA-mRNA pairs according to 38 hallmark pathways. Effects on distinct pathways are represented by colors indicating enrichment scores. miR-29 represents miR-29a/b/c.

**Integrated miRNA-mRNA analysis.** To identify target mRNAs of the 20 differentially expressed miRNAs in kidneys from placebo-treated 5/6 Nx rats, RNA was sequenced from the corresponding kidney tissues. The principal component analysis revealed that most of the expression profiles of the sham + placebo rats clustered separately to the 5/6 Nx groups whereas the treated 5/6 Nx groups are spread across the 5/6 Nx groups (Supplementary data, Fig. S3). Deregulated miRNA expression is depicted in the heat map in Fig. 3 and all deregulated genes are summarized in Supplementary Table 2. In total, the expression of 1404 genes is deregulated (1.5-fold; \( P < 0.05 \)) in placebo-treated 5/6 Nx rats compared to the sham-operated control rats: the expression of 1015 genes is up-regulated whereas the expression of 389 genes is down-regulated. The effects of telmisartan and linagliptin on these deregulated genes are shown in Fig. 3 and summarized in Supplementary Table 2.

Integrating miRNAs and their corresponding target mRNAs (both 1.5-fold deregulated at \( P < 0.05 \)), resulted in 113 renal miRNA/target mRNA pairs with a Spearman's correlation coefficient \( r_s < −0.7 \). The predicted targets displayed in Table 2 are based on either experimental observations or a high level of prediction. Inverse correlations were observed for the four up-regulated miRNAs miR-532-5p, miR-199a-5p, miR-199a-3p and miR-142-3p and the two down-regulated miRNAs miR-203 and miR-29. The effects of telmisartan and/or linagliptin on these identified miRNA/target mRNA pairs are characterized by the loss of Spearman’s correlation coefficient of \( r_s < −0.7 \).

To further characterize the effects of telmisartan and linagliptin on the effects of mRNA-miRNA interactions in 5/6-Nx rats pathway analysis was performed using MSigDB. Hypergeometric testing using the hallmark gene set from MSigDB revealed that the down-regulated miRNAs corresponds to up-regulated target mRNAs that are involved in fibrotic pathways, such as epithelial mesenchymal transition and inflammatory processes, such as TNF\( \alpha \) signaling, IL-6/JAK/STAT3 signaling or IL-2/STAT5 signaling (Fig. 4). Down-regulated mRNAs that correspond to up-regulated miRNAs are involved in oxidative phosphorylation and adipogenesis (Fig. 4).

**Urinary exosomal miRNA expression profiling.** To assess which of the aforementioned treatment affected miRNA expression profiles are reflected in urinary exosomes qRT-PCR was employed using TaqMan Array Cards, which contain all deregulated miRNAs described above. Only miRNAs with the highest expression levels in the kidney - miR-21, miR-29b, miR-29c and miR-203 - could be detected in urinary exosomes. The levels of miR-21 and miR-203 were not affected across all groups in urinary exosomes. Urinary exosomal levels of miR-29b and miR-29c were decreased in placebo-treated 5/6 Nx rats compared to the sham-operated group. Telmisartan significantly restored the levels of both urinary exosomal miRNAs miR-29b and miR-29c whereas
linagliptin restored the level of only miR-29c compared to the 5/6 Nx placebo group (Fig. 5a). Correlation analysis revealed that down-regulated urinary exosomal miR-29c expression was significantly negatively correlated with increasing UACR ($r^2 = -0.81; P = 0.0003$, Fig. 5b).

**Discussion**

This study shows that the DPP-4 inhibitor linagliptin and the ARB telmisartan induced effects on renal miRNA and their corresponding target mRNA expression in non-diabetic 5/6 Nx rats. Integrating both renal miRNA and mRNA expression profiles enriched pathways, which are deregulated in 5/6 Nx rats, such as fibrotic pathways including epithelial mesenchymal transition and inflammatory processes, such as TNFα signaling, IL-6/JAK/STAT3 signaling or IL-2/STAT5 signaling. In particular, telmisartan and linagliptin exert their strongest effects on fibrotic processes.

Recently it was demonstrated that linagliptin was comparable to telmisartan in preventing CKD progression in non-diabetic, non-glucose dependent 5/6 Nx rats. Tsuprykov et al. demonstrated that linagliptin's action was pronounced with respect to reduction of renal interstitial fibrosis and glomerular hypertrophy, whereas telmisartan's beneficial action was mostly due to its blood pressure-lowering effect. In this study, among all 14,605 sequenced mRNAs and 420 detected miRNAs in the kidney both mRNA and miRNA expression levels were not

---

**Figure 5.** Urinary exosomal miRNA expression. Urinary exosomal levels of miR-21, miR-203, miR-29b and miR-29c in sham-operated (green), placebo-treated 5/6 Nx (red), telmisartan-treated (blue) and linagliptin-treated 5/6 Nx (yellow). (a) Relative urinary exosomal miRNA expression analyzed by qRT-PCR was normalized to the mean expression of sham-operated control rats. Significant differences 5/6 Nx + placebo are indicated by *($P < 0.05$). (b) Correlation between fold change of urinary exosomal miR-29c expression and UACR. Data were compared by Spearman's correlation coefficient.
significantly different between telmisartan and linagliptin treated 5/6 Nx rats. Nevertheless, the extent of the beneficial effects exerted by each drug was different. The expression of one gene, namely Renin, was approximately 16-fold (adj- P-value = 0.4) stronger induced in the kidneys of telmisartan treated 5/6 Nx rats compared to linagliptin-treated rats. There was a trend that the beneficial effects characterized by the effects on the deregulated expression levels in 5/6 Nx are more pronounced after telmisartan treatment compared to linagliptin treatment (Table S2). Moreover, a combination of telmisartan and linagliptin might have additive effects as demonstrated by Alter et al.34. However, this was not investigated in this study and should be considered in future studies. The pharmacological effects of telmisartan and linagliptin are attributed to the interference with multiple pathways. An overlap on gene expression level has been previously described35 and confirmed here in addition with miRNA expression level. It is worthwhile to mention that the extent of deregulation is different for individual pathways. Nevertheless, proteomic analyses revealed that post-translational modifications might further differentiate the mechanisms of both drugs36. In particular, linagliptin induced a significant upregulation of the HNRNPA1 fragment, an important regulator of the atrial natriuretic peptide-dependent guanylate cyclase pathway, which might contribute to the anti-fibrotic effects. Further investigations are needed to integrate all omics approaches (mRNomics, transcriptomics, proteomics) to further dissect the mode of action of both drugs. In contrast to animal models of diabetic CKD37,38 and kidney cell lines exposed to high glucose concentrations39 the TGFβ/SMAD2/3 pathway which is a hallmark of renal fibrosis was not directly modulated by linagliptin in the non-diabetic 5/6 Nx model. Nevertheless, indirect modulation of renal fibrosis can occur via pro- and anti-fibrotic miRNAs and our study shows that the degree of deregulation of the renal miRNA expression correlates with increasing interstitial fibrosis.

The renal expression of the up-regulated pro-fibrotic miRNAs miR-150, miR-199a-3p and miR-199a-5p is significantly attenuated after telmisartan or linagliptin treatment. miR-199a-5p is up-regulated during the fibrogenic response to tissue injury11 and is a general marker for fibrogenesis in various animal models such as bleomycin-induced lung fibrosis, CCl4-induced liver fibrosis and unilateral ureteral obstruction model of kidney fibrosis13. Our study revealed that most of the protein-encoding genes potentially regulated by miR-199a-5p are involved in cytoskeletal organization and cell proliferation processes such as ARHGGEF5, VEGFA or SDPR. SDPR encodes Cavin 2, which is involved in maintaining endothelial morphology and function40 and inhibition of Cavin 2 expression might cause a loss of cellular integrity and accelerate endothelial mesenchymal transition.

Using different CKD models it was shown that members of the miR-29 family (miR-29a) protect against renal fibrosis by inhibiting endothelial mesenchymal transition and preventing the deposition of ECM41,42. The miR-29 family members share a common seed region sequence and are predicted to target the same genes. However, differential regulation of members of the miR-29 family might be a result of the subcellular distribution, suggesting their functional consequence may not be identical. Our study revealed that the expression of miR-29a is not altered between experimental groups. In previous studies it appeared that the three miR-29s may be regulated by distinct mechanisms. In the renal medulla of the Dahl salt-sensitive (SS) rat and a consomic rat strain derived from it, miR-29a is more abundantly expressed compared to miR-29b and miR-29c and the three miR-29 species respond differently to 3 days of a high-salt diet, which might be a consequence of distinct post-transcriptional processing43. In addition, our study does not distinguish between miR-29s-3p and -5p-arms. Nevertheless, it is expected that both arms are affected during fibrotic processes in the kidney43,44. Predicted target genes for the miR-29 family members largely overlap35 which includes genes encoding proteins that are involved in the synthesis of the ECM, including collagen isoforms, laminins, fibrilins, elastins, matrix metalloproteinases, and integrins45,46. It is well known that TGFβ/Smad signalling negatively regulates the expression of miR-29s and that DPP-4 inhibitors are able to normalize these changes45,46. The present study shows that linagliptin/telmisartan-induced restoration of renal miR-29s expression was accompanied with a decrease in direct target miRNA expression of ECM genes such as COL1A1, COL1A2, COL3A1, COL4A1, COL11A1, FBN1 and MMP2. A similar relation was observed between linagliptin and telmisartan induced changes in miR-29b/c level and collagen type III protein expression (not significant) (Fig. S4). Moreover, normalized miR-29s levels are associated with decreased expression of TGFβ2 and BMP1.

In the non-diabetic 5/6 Nx model, CKD progression is more pronounced in 5/6 Nx rats compared to 5/6 Nx mice. This is characterized by a marked increase in renal interstitial fibrosis and markers for glomerular filtration rate, such as cystatin C, in 5/6 Nx rats compared to 5/6 Nx mice. Furthermore, renal gene expression representing markers of renal fibrosis and inflammation, such as COL1A1, COL1A3, TIMP1 and TGF-β, are significantly increased in 5/6 Nx rats compared to 5/6 Nx mice35,38. Overall, it seems that mice tolerate the 5/6 Nx surgery better than rats. 5/6 Nx surgery results in only moderate effects on both mRNA and miRNA expression in mice, which might contribute to the different impact in treatment effects of linagliptin between mice and rats. Moreover, the kidney fibrosis phenotype in mice is largely dependent upon the strain specificity39. In addition, Srivastava et al.38 observed discrepancies regarding miR-29s expression level between diabetic mice (STZ treated CD-1 mice) and less fibrotic diabetic 129Sv mice.

Recent studies revealed that miR-29s levels in urinary exosomes are significantly decreased in CKD patients41 and in patients with lupus nephritis42. Our study demonstrates that linagliptin/telmisartan induced restoration of miR-29c levels can be demonstrated in urinary exosomes highlighting the importance of urinary exosomes as potential biomarkers for disease progression and monitoring of treatment effects. Moreover, miR-29c levels in urinary exosomes correlate with renal function (albuminuria). One prospective, randomized, controlled study including urine sampling has been completed recently (the MARLINA-T2D trial; Efficacy, Safety and Modification of Albuminuria in Type 2 Diabetes Subjects with Renal Disease with LINAglptin) to investigate potential short-term albuminuria-lowering effects of linagliptin43. In the MARLINA study, individuals at early stages of diabetic kidney disease were included and it was demonstrated that linagliptin significantly improved glycemic control but did not significantly lower albuminuria; in addition, there was no significant change in eGFR44. Furthermore, detection of clinically relevant renal effects of linagliptin may require longer treatment.
The long-term effects of linagliptin renal outcomes were assessed in the CARmELINA (NCT01897532) study. Urine samples obtained from this study could be used to further substantiate the current findings. The CARmELINA study demonstrated positive effects of linagliptin on progression of albuminuria category - change from non-albuminuria to micro/macroalbuminuria or change from microalbuminuria to macroalbuminuria ($P = 0.003^{41,42}$. Our latest study indicated that the renoprotective effects of linagliptin cannot solely be attributed to the GLP-1/GLP-1R pathway, highlighting the importance of other signaling pathways influenced by DPP-4 inhibition such as collagen I homeostasis, HNRNPA1, YB-1, thyrosmin [34 and TGF-β$^3$]^{38,39}.

Our study showed that the linagliptin and telmisartan-induced restorative effects on miR-29c expression were reflected in urinary exosomes, suggesting that miRNA profiling of urinary exosomes might be used as a useful biomarker for addressing effects during CKD progression and treatment with drugs, since urinary miRNAs are easily to access. This might be of particular impact for human studies, because in human studies kidney tissue to analyze treatment effects are usually not available.

Received: 4 October 2019; Accepted: 11 February 2020;
Published online: 25 February 2020

References
1. Jha, V. et al. Chronic kidney disease: global dimension and perspectives. *Lancet*. **382**, 260–272 (2013).
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis.* **39**, S1–S266 (2002).
3. Snively, C. S. & Gutierrez, C. Chronic kidney disease: prevention and treatment of common complications. *Am Fam Physician.* **70**, 1921–1928 (2004).
4. Shankar, Y. et al. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. *J Hypertens.* **32**, 2211–2223 (2014).
5. Alter, M. L. et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. *Kidney Blood Press Res.* **36**, 119–130 (2012).
6. Mulvihill, E. E. & Drucker, D. J. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. *Endocr Rev.* **35**, 992–1019 (2014).
7. Zhu, F. et al. DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/ M2 Macrophage Polarization. *Diabetes.* **65**, 2966–2979 (2016).
8. Takashima, S. et al. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. *Kidney Int.* **90**, 783–796 (2016).
9. Kanasi, K. et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. *Diabetes.* **63**, 2120–2131 (2014).
10. Trionfini, P., Benigni, A. & Remuzzi, G. MicroRNAs in kidney physiology and disease. *Nat Rev Nephrol.* **11**, 23–33 (2015).
11. Lai, J. Y. et al. MicroRNA-21 in glomerular injury. *Am J Nephrol.* **26**, 805–816 (2015).
12. Liu, W. et al. Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD. *Physiol Genomics.* **50**, 20–34 (2018).
13. Liu, C. L. et al. miR-199a-5p is upregulated during fibrogenic response to tissue injury and mediates TGFβ-induced lung fibroblast activation by targeting caveolin-1. *Plos Genet.* **9**, e1003291 (2013).
14. Liu, L. L. et al. MicroRNA-29c in urinary exosome/microvesicle as a biomarker of renal fibrosis. *Am J Physiol Ren Physiol.* **305**, F1220–1227 (2013).
15. Qin, W. et al. TGF-β3/Mad3 signaling promotes renal fibrosis by inhibiting miR-29. *J Am Soc Nephrol.* **22**, 1462–1474 (2011).
16. Liu, Y. et al. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. *Hypertension.* **55**, 974–982 (2010).
17. Lin, C. L. et al. MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction. *J Am Soc Nephrol.* **25**, 1698–709 (2014).
18. Erdbrügger, U. & Le, T. H. Extracellular Vesicles in Renal Diseases: More than Novel Biomarkers? *J Am Soc Nephrol.* **27**, 12–26 (2016).
19. Ramezani, A. et al. Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study. *Eur J Clin Invest.* **45**, 394–404 (2015).
20. Barutta, F. et al. Urinary exosomal micro-RNAs in incipient diabetic nephropathy. *Plos One.* **8**, e37798 (2013).
21. Delic, D. et al. Urinary Exosomal miRNA Signature in Type II Diabetic Nephropathy Patients. *Plos One.* **11**, e0150154 (2016).
22. Solé, C., Cortés-Hernández, J., Felip, M. L., Vidal, M. & Ordí-Ros, J. miR-29c in urinary exosomes as predictor of early renal fibrosis in lupus nephritis. *Nephrol Dial Transplant.* **30**, 1488–1496 (2015).
23. Tsyupyrov, O. et al. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. *Kidney Int.* **89**, 1049–1061 (2016).
24. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT(T)) Method. *Methods.* **25**, 402–408 (2001).
25. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* **43**, e47 (2015).
26. Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol.* **3**, Article3 (2004).
27. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society Series B (Methodological).* **289–300 (1995).
28. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA.* **102**, 15545–15550 (2005).
29. Gangadharan Komala, M., Gross, S., Zaky, A., Pollock, C. & Panchalpaksan, U. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes. *Nephrology (Carlton).* **21**, 423–31 (2016).
30. Gangadharan Komala, M., Gross, S., Zaky, A., Pollock, C. & Panchalpaksan, U. Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFβ through Interaction with CIME6P and Limits Renal Tubulointerstitial Fibronectin. *Plos One.* **10**, e0141143 (2015).
31. Hanssen, C. G., Shrets, E., Howard, G., Riento, K. & Nichols, B. J. Deletion of cavin genes reveals tissue-specific mechanisms for morphogenesis of endothelial caveolae. *Nat Commun.* **4**, 1831 (2013).
32. Chung, A. C., Yu, X. & Lan, H. Y. MicroRNA and nephropathy: emerging concepts. *Int J Nephrol Renovasc Dis.* **6**, 169–179 (2013).
33. Ramdas, V., McBride, M., Denby, L. & Baker, A. H. Canonical transforming growth factor-β signaling regulates desintegrin metalloprotease expression in experimental renal fibrosis via miR-29. *Am J Pathol.* **183**, 1885–1896 (2013).
34. Srivastava, S. P. et al. Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis. *Sci Rep.* **6**, 29884 (2016).
35. Kriegel, A. J., Liu, Y., Fang, Y., Ding, X. & Liang, M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics. 44, 237–244 (2012).
36. Sengupta, S. et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 105, 5874–5878 (2008).
37. Van Rooij, E. et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 105, 13027–13032 (2008).
38. Hasan, A. A. et al. Mechanisms of GLP-1 receptor–independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy. Kidney Int. 95, 1373–1388 (2019).
39. Sugimoto, H., Grahovac, G., Zeisberg, M. & Kalluri, R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes. 56, 1825–33 (2007).
40. Groop, P. H. et al. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial. Diab Vasc Dis Res. 12, 455–462 (2015).
41. Perkovic, V., Toto, R. & Cooper, M. E. Effect of linagliptin on kidney and cardiovascular outcomes in patients with type 2 diabetes and kidney disease: CARMELINA. Am Soc Nephrol. 29, 1314 (2018).
42. Rosenstock, J. et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 321, 69–79 (2019).

Acknowledgements
A.A.H. was supported by a PhD scholarship from D.A.A.D. (German Academic Exchange Service). The manuscript wording was thoroughly checked by Jonathon Gibbs (Envision Pharma Group).

Author contributions
B.H., T.K. and D.D. designed the study. K.R., M.R., O.T. and A.A.H. carried out the experiments. O.G., F.W. P.B. and D.D. analyzed the results. D.D., R.U., B.H. and T.K. wrote the paper. D.D., F.W., R.U., O.G., K.R., M.R., O.T., A.A.H., B.K.K., P.B., A.K., F.G., M.M., B.H. and T.K. revised the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-60336-4.

Correspondence and requests for materials should be addressed to D.D. or B.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020